Internal Reference Number: FOI_9107
Date Request Received: 18/12/2025 00:00:00
Date Request Replied To: 29/12/2025 00:00:00
This response was sent via: By Email
Request Summary: Multiple Myeloma
Request Category: Researcher
| Question Number 1: I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. | |
| Answer To Question 1: Please see our response to all questions in the attached spreadsheet. To accompany this answer to question 1 please also see the documents listed below:  13408 - FOI_9107 - Multiple Myeloma - FOR ISSUE v1.xlsx | |
| Question Number 2: Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] ± Dexamethasone • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Daratumumab [Darzalex] monotherapy • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) • Lenalidomide [Revlimid] + Dexamethasone • Lenalidomide [Revlimid] monotherapy • Panobinostat + Bortezomib + Dexamethasone • Pomalidomide [Imnovid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapy [please specify] | |
| Answer To Question 2: Please see our response to all questions in the attached spreadsheet. | |
| Question Number 3: In the last 6 months, how many patients have been initiated* on the following regimens? • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Lenalidomide [Revlimid] monotherapy • Lenalidomide [Revlimid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Any other systemic anti-cancer therapy [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation. | |
| Answer To Question 3: Please see our response to all questions in the attached spreadsheet. | |
| Question Number 4: In the last 6 months, how many patients have received the following second-line treatment? • Lenalidomide [Revlimid] + Dexamethasone | |
| Answer To Question 4: Please see our response to all questions in the attached spreadsheet. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
